BDNF

Brain-derived neurotrophic factor (BDNF) is a neurotrophin primarily produced in the brain, particularly in neurons and astrocytes, that plays a crucial role in neuronal survival, growth, and synaptic plasticity. Researchers primarily study BDNF for its involvement in cognitive functions and its potential link to various neurological and psychiatric disorders. Key findings indicate that exercise can significantly increase BDNF levels, which may mediate improvements in cognition and mood, while lower BDNF levels have been associated with conditions such as post-stroke depression and diabetes. Current research is focused on understanding the physiological roles of BDNF in different brain regions and its implications in neuropathologies, highlighting its potential as a target for clinical interventions. As studies continue to explore the therapeutic applications of BDNF, its significance in brain health and disease remains a prominent area of investigation.

Brain-Derived Neurotrophic Factor (BDNF), also known as Abrineurin, is an endogenous neurotrophin primarily produced in the brain. It belongs to the growth factor category and is abundantly expressed in the central nervous system. BDNF is synthesized by neurons and glial cells, including astrocytes, and plays a crucial role in neuronal survival, development, and synaptic plasticity. Researchers have extensively studied BDNF due to its significant involvement in brain functions and its potential therapeutic implications. BDNF is involved in various physiological processes, including cognitive functions, mood regulation, and neural repair. It has been implicated in conditions such as depression, diabetes, and spinal cord injuries. Research has shown that BDNF levels can be influenced by factors such as exercise, which is associated with improved cognition and mood. Moreover, BDNF's role in post-stroke depression and diabetes-related brain function impairment is being actively investigated. BDNF exerts its effects primarily through binding to the TrkB receptor, initiating a cascade of intracellular signaling pathways that promote neuronal survival, differentiation, and synaptic plasticity. This signaling involves pathways such as PI3K/Akt, MAPK/ERK, and PLCγ, which contribute to its diverse biological effects. Pharmacokinetic properties of BDNF, such as half-life and bioavailability, are not well-documented, particularly for different administration routes. However, researchers have explored novel delivery methods, such as intranasal administration, to enhance its therapeutic potential. Clinically, BDNF is not yet approved as a therapeutic agent, but its potential in treating neurological disorders and enhancing neuroprotection is under investigation. Regulatory standing varies by region, with ongoing research into its clinical applications.

BDNF acts primarily on the TrkB receptor, activating intracellular signaling pathways such as PI3K/Akt, MAPK/ERK, and PLCγ. These pathways lead to enhanced neuronal survival, differentiation, and synaptic plasticity, contributing to its neuroprotective and neurotrophic effects.

Brain-derived neurotrophic factor (BDNF) primarily exerts its effects through the activation of tropomyosin receptor kinase B (TrkB) receptors, initiating signaling cascades such as the phosphoinositide 3-kinase (PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK) pathway. These pathways are crucial for promoting neuronal survival, differentiation, synaptic plasticity, and neurogenesis. While the mechanisms of BDNF action are well-studied, the full extent of its interactions with astrocytes and the nuances of its signaling in various brain regions remain incompletely understood.

Current evidence is limited regarding the specific physiological roles of BDNF in astrocytes, particularly how these roles vary across different brain regions and developmental stages. Further research is needed to clarify the mechanisms by which BDNF influences mood disorders such as post-stroke depression, including the interaction between pre-existing BDNF levels and the hypoxic environment post-stroke. Additionally, larger randomized controlled trials are required to better understand the impact of exercise on BDNF levels in diverse populations, particularly focusing on sex differences and the effects in individuals with diabetes, where findings have been inconsistent.